Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02705482
Registration number
NCT02705482
Ethics application status
Date submitted
22/09/2015
Date registered
10/03/2016
Date last updated
26/08/2019
Titles & IDs
Public title
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Query!
Scientific title
A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Query!
Secondary ID [1]
0
0
D6060C00002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Select Advanced Solid Tumors
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - MEDI0562
Other interventions - Tremelimumab
Other interventions - Durvalumab
Experimental: Arm A: MEDI0562 and durvalumab - MEDI0562 and durvalumab
Experimental: Arm B: MEDI0562 and tremelimumab - MEDI0562 and tremelimumab
Other interventions: MEDI0562
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
Other interventions: Tremelimumab
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
Other interventions: Durvalumab
Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety as defined by the presence of adverse events (AE), serious adverse events (SAE), and dose limiting toxicities (DLT).
Query!
Assessment method [1]
0
0
The primary endpoint is safety as assessed by presence of adverse event (AE), serious adverse event (SAE), and dose limiting toxicity (DLT).
Query!
Timepoint [1]
0
0
From time of informed consent through 12 weeks after ending treatment with investigational product
Query!
Secondary outcome [1]
0
0
Preliminary Antitumor Activity:Best Overall Response
Query!
Assessment method [1]
0
0
The endpoints for assessment of antitumor activity include Best Overall Response (BOR) and will be based on all post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy
Query!
Timepoint [1]
0
0
At approximately 3 time points through Day 113.
Query!
Secondary outcome [2]
0
0
Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: Cmax
Query!
Assessment method [2]
0
0
The endpoints for assessment of PK of MEDI0562 and durvalumab or tremelimumab include individual MEDI0562, durvalumab, and tremelimumab concentrations at different time points after administration. PK parameters that may be modeled on these data include, but are not limited to, maximum observed concentration (Cmax).
Query!
Timepoint [2]
0
0
To be assessed at approximately 12 clinic visits through Day 113
Query!
Secondary outcome [3]
0
0
Immunogenicity
Query!
Assessment method [3]
0
0
The endpoints for assessment of immunogenicity of MEDI0562, durvalumab, and tremelimumab include the number and percentage of subjects who develop detectable anti drug antibodies (ADAs).
Query!
Timepoint [3]
0
0
At approximately 8 time points through Day 113.
Query!
Secondary outcome [4]
0
0
Pharmacodynamic Activity
Query!
Assessment method [4]
0
0
The endpoints for assessment of pharmacodynamic activity include induction of proliferation markers in various lymphocyte populations and assessment of tumor-infiltrating lymphocytes (TILs) in tumor biopsy specimens.
Query!
Timepoint [4]
0
0
At approximately 12 time points through Day 113.
Query!
Secondary outcome [5]
0
0
Preliminary Antitumor Activity: Disease Control
Query!
Assessment method [5]
0
0
The endpoints for assessment of antitumor activity include disease control and is defined as CR, PR, or SD according to RECIST v1.1
Query!
Timepoint [5]
0
0
At approximately 3 time points through Day 113.
Query!
Secondary outcome [6]
0
0
Preliminary Antitumor Activity: Duration of Response
Query!
Assessment method [6]
0
0
The endpoints for assessment of antitumor activity include duration of response (DoR) and is defined as the duration from the first documentation of OR to the first documentation of disease progression or death due to any cause.
Query!
Timepoint [6]
0
0
At approximately 3 time points through Day 113.
Query!
Secondary outcome [7]
0
0
Preliminary Antitumor Activity: Progression-free Survival
Query!
Assessment method [7]
0
0
The endpoints for assessment of antitumor activity include progression-free survival (PFS) and is defined as the duration measured from the start of treatment with investigational product to the first documentation of disease progression or death due to any cause
Query!
Timepoint [7]
0
0
At approximately 3 time points through Day 113.
Query!
Secondary outcome [8]
0
0
Preliminary Antitumor Activity: Overall Survival
Query!
Assessment method [8]
0
0
The endpoints for assessment of antitumor activity include overall survival (OS) and is defined as the time from the start of treatment with Investigational Product until death due to any cause.
Query!
Timepoint [8]
0
0
At approximately 3 time points through Day 113.
Query!
Secondary outcome [9]
0
0
Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: AUC
Query!
Assessment method [9]
0
0
The endpoints for assessment of PK of MEDI0562 and durvalumab or tremelimumab include individual MEDI0562, durvalumab, and tremelimumab concentrations at different time points after administration. PK parameters that may be modeled on these data include area under the concentration-time curve (AUC).
Query!
Timepoint [9]
0
0
To be assessed at approximately 12 clinic visits through Day 113
Query!
Secondary outcome [10]
0
0
Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: Clearance
Query!
Assessment method [10]
0
0
The endpoints for assessment of PK of MEDI0562 and durvalumab or tremelimumab include individual MEDI0562, durvalumab, and tremelimumab concentrations at different time points after administration. PK parameters that may be modeled on these data include clearance (CL).
Query!
Timepoint [10]
0
0
To be assessed at approximately 12 clinic visits through Day 113
Query!
Secondary outcome [11]
0
0
Pharmacokinetics of MEDI0562/durvalumab or MEDI0562/tremelimumab: t½
Query!
Assessment method [11]
0
0
The endpoints for assessment of PK of MEDI0562 and durvalumab or tremelimumab include individual MEDI0562, durvalumab, and tremelimumab concentrations at different time points after administration. PK parameters that may be modeled on these data include terminal phase half-life (t½).
Query!
Timepoint [11]
0
0
To be assessed at approximately 12 clinic visits through Day 113
Query!
Secondary outcome [12]
0
0
Preliminary Antitumor Activity: Objective Response
Query!
Assessment method [12]
0
0
The endpoints for assessment of antitumor activity include objective response (OR) and is defined as confirmed CR or confirmed PR based on RECIST v1.1
Query!
Timepoint [12]
0
0
At approximately 3 time points through Day 113.
Query!
Secondary outcome [13]
0
0
Preliminary Antitumor Activity: Time to Response
Query!
Assessment method [13]
0
0
The endpoints for assessment of Time to Response TTR and is defined as the time of first treatment to a subsequently confirmed CR or confirmed PR based on RECIST v1.1
Query!
Timepoint [13]
0
0
At approximately 3 time points through Day 113.
Query!
Secondary outcome [14]
0
0
Preliminary Antitumor Activity: Percent Change from Baseline
Query!
Assessment method [14]
0
0
The endpoints for assessment percent change from baseline in target lesion sum of diameters will be calculated at each adequate post baseline disease assessment with recorded measurement for all target lesions defined at baseline.
Query!
Timepoint [14]
0
0
At approximately 3 time points through Day 113.
Query!
Eligibility
Key inclusion criteria
Subjects must meet all of the following criteria:
1. Written and signed informed consent.
2. Age = 18 years at the time of study entry.
3. Subjects must have received and have progressed, are refractory, or are intolerant to
standard therapy appropriate for the specific tumor type. Subjects should not have
received more than 3 prior lines of systemic therapy for recurrent or metastatic.
4. Subjects in the dose-escalation phase, must have histologic documentation of advanced
solid tumors, excluding primary CNS tumors and hematologic malignancies.
5. Subjects in the dose-expansion phase, must have recurrent or metastatic disease solid
tumors according to treatment arm as specified in the protocol.
6. Subjects who have received prior therapy with regimens containing CTLA 4, PD L1, or PD
1 antagonists are permitted to enroll if additional protocol criteria are met.
7. Subjects must have at least 1 lesion that is measurable using RECIST guidelines.
8. Subjects must consent to provide archived tumor specimens for correlative biomarker
studies. In the setting where archival material is unavailable or unsuitable for use,
subjects must consent and undergo fresh tumor biopsy.
9. All subjects are encouraged to consent to and provide both pretreatment and on
treatment tumor biopsies.
10. ECOG Performance score of 0 or 1, unless protocol exceptions are met.
11. In the opinion of the investigator likely to complete = 8 weeks of treatment.
12. Adequate hematologic, renal and hepatic function as determined by blood laboratory
values.
13. At the time of Day 1 of the study, subjects with CNS metastases must have been treated
and must be asymptomatic and meet the following:
1. No concurrent treatment, inclusive of, but not limited to surgery, radiation,
and/or corticosteroids
2. At least 42 days without progression of CNS metastases as evidenced by magnetic
resonance imaging (MRI) or computed tomography (CT) after last day of treatment
3. At least 14 days since last dose of corticosteroids Note: Subjects with
leptomeningeal disease or cord compression are excluded from the study.
14. Female subjects of childbearing potential who are sexually active with a
non-sterilized male partner must use at least 1 highly effective method of
contraception from screening, and must agree to continue using such precautions for
180 days after the final dose of investigational product.
15. Non-sterilized male subjects who are sexually active with a female partner of
childbearing potential must use male condom plus, if locally available, spermicide
from Day 1 and for 180 days after receipt of the final dose of investigational
product.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Any of the following would exclude the subject from participation in the study:
1. Prior treatment with TNFRSF agonists
2. Prior treatment with IMT for certain disease types may be restricted per protocol.
3. History of severe allergic reactions to any unknown allergens or any components of the
study drug formulations
4. Active or prior documented autoimmune disease within the past 2 years.
5. Concurrent enrollment in another clinical study, unless it is an observational
clinical study or the follow up period of an interventional study
6. Receipt of any conventional or investigational anticancer therapy not otherwise
specified above within 28 days prior to the first dose
7. Any concurrent chemotherapy, IMT, or biologic or hormonal therapy for cancer
treatment.
8. Unresolved toxicities from prior anticancer therapy.
9. Systemic therapeutic anticoagulation or daily aspirin dose exceeding 325 mg/per day.
10. Current or prior use of immunosuppressive medication within 14 days prior to the first
dose of MEDI0562 with exceptions as per protocol.
11. History of primary immunodeficiency, solid organ transplantation, or tuberculosis
12. Test results indicating active infection with human immunodeficiency virus (HIV) or
hepatitis B or C defined by positive serologic testing and confirmatory viral nucleic
acid testing
13. Pregnant or breastfeeding women
14. Major surgery within 4 weeks prior to first dose of MEDI0562 or still recovering from
prior surgery.
15. Other invasive malignancy within 2 years with the exception of protocol specified
criteria
16. Any uncontrolled intercurent illness or condition that, in the opinion of the
investigator, would interfere with evaluation of the investigational product or
interpretation of subject safety or study results.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/03/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
7/08/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
58
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Missouri
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New Mexico
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Villejuif
Query!
Country [11]
0
0
Netherlands
Query!
State/province [11]
0
0
Amsterdam
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
MedImmune LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic
agents in adult subjects with select advanced solid tumors.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02705482
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02705482
Download to PDF